European health authorities are reporting a sharp rise in gonorrhea and syphilis cases—including in the Netherlands—driven by antibiotic resistance and behavioral shifts post-pandemic. Gonorrhea infections surged 23% across the EU in 2025, while syphilis cases rose 18%, with Neisseria gonorrhoeae strains now exhibiting resistance to ceftriaxone (the last-line cephalosporin) in 4.2% of isolates. Public health officials warn of a “silent epidemic” among men who have sex with men (MSM) and heterosexual populations, compounded by delayed diagnoses due to asymptomatic presentations in up to 50% of early-stage syphilis.
This resurgence isn’t just a European issue—it reflects a global trend. The World Health Organization (WHO) declared antimicrobial resistance (AMR) in gonorrhea a “major public health threat” in 2022, yet progress on new treatments has stalled. Meanwhile, Dutch clinics report a 30% increase in syphilis cases among young adults (15–24 years) since 2024, with Treponema pallidum strains increasingly linked to late-stage complications like neurosyphilis. The question isn’t if these infections will spread further, but how healthcare systems will adapt before resistance renders current therapies obsolete.
In Plain English: The Clinical Takeaway
- Antibiotics are failing: Gonorrhea and syphilis are becoming harder to treat because bacteria are evolving resistance to the drugs we rely on most.
- You might not know you’re infected: Up to half of early syphilis cases and many gonorrhea infections cause no symptoms, so regular testing is critical—especially if you’re sexually active.
- This isn’t just a “gay men’s disease”: While MSM are disproportionately affected, heterosexual transmission is rising, particularly in urban areas with high STI prevalence.
Why Europe’s STI Surge Matters: The Science Behind the Numbers
The recent spike in gonorrhea and syphilis isn’t random—it’s the result of three interlocking factors: antibiotic overuse, diagnostic delays, and behavioral changes post-COVID-19. Here’s how they interact:
- Antimicrobial Resistance (AMR): Neisseria gonorrhoeae has developed plasmid-mediated resistance to azithromycin (a first-line treatment) in 12% of European isolates, per the European Centre for Disease Prevention and Control (ECDC). Syphilis, while treatable with penicillin, now faces macrolide-resistant strains in 8% of cases, complicating therapy for penicillin-allergic patients.
- Delayed Diagnoses: The pandemic disrupted STI screening programs. In the Netherlands, chlamydia and gonorrhea testing dropped by 40% in 2020–2021, creating a backlog of undiagnosed infections that now fuel transmission chains. Syphilis, often asymptomatic in early stages, can go unnoticed for years, leading to irreversible damage (e.g., cardiovascular syphilis or neurosyphilis).
- Behavioral Shifts: Data from the WHO European Sexual Health Report 2023 shows a 28% increase in condomless sex among young adults since 2019, partly due to pandemic-related stress and reduced access to contraception.
Geo-Epidemiological Bridging: How This Affects Local Healthcare Systems
Europe’s STI crisis isn’t isolated—it mirrors patterns in the U.S. And Asia, but with critical regional differences in healthcare infrastructure:
- Netherlands: The Dutch GGD (Public Health Services) has ramped up rapid antigen testing for gonorrhea in high-prevalence areas (e.g., Amsterdam, Rotterdam), but capacity remains strained. A 2025 study in Euro Surveillance found that 72% of gonorrhea cases in the Netherlands were linked to MSM networks, yet heterosexual transmission is now the fastest-growing vector.
- Germany: Berlin’s Charité University Hospital reported a 50% increase in neurosyphilis cases in 2025, prompting the German Federal Ministry of Health to classify syphilis as a “notifiable disease” under stricter surveillance laws. However, stigma and lack of public awareness hinder early intervention.
- UK (NHS): The UK Health Security Agency (UKHSA) issued a Level 3 alert (the second-highest tier) for ceftriaxone-resistant gonorrhea in 2026, advising clinicians to use combination therapy (ceftriaxone + azithromycin) despite limited efficacy. The NHS is piloting point-of-care PCR testing in sexual health clinics to reduce diagnostic delays.
The European Medicines Agency (EMA) has accelerated reviews for two experimental treatments:
- Gepotidacin (GSK2251052): A novel DNA gyrase inhibitor in Phase III trials (N=1,500) showing 95% efficacy against ceftriaxone-resistant gonorrhea. If approved, it could bridge the treatment gap—but regulatory hurdles remain due to its QT-prolongation risk.
- Zoliflodacin (ETX1594): A spirotetronamide targeting gyrase B, with Phase IIb data (N=300) demonstrating 98% cure rates for uncomplicated gonorrhea. The EMA’s Committee for Medicinal Products for Human Use (CHMP) is reviewing it under conditional approval pathways.
| Pathogen | Key Resistance Mechanisms (2026) | Current First-Line Treatment | Emerging Alternatives | EMA/FDA Status |
|---|---|---|---|---|
| Neisseria gonorrhoeae | Plasmid-mediated azithromycin resistance (12% EU), penA mutations reducing ceftriaxone susceptibility (4.2%) | Ceftriaxone 500mg IM + azithromycin 2g PO (dual therapy) | Gepotidacin, zoliflodacin, solithromycin (macrolide) | Gepotidacin: Phase III (EMA review 2027); Zoliflodacin: Conditional approval under discussion |
| Treponema pallidum (syphilis) | Macrolide resistance (8% EU), penicillin allergy (15% of cases) | Benzathine penicillin G 2.4MU IM (single dose) | Doxycycline (for penicillin-allergic patients), ceftriaxone (neurosyphilis) | No new antibiotics in pipeline; doxycycline efficacy under scrutiny |
Funding and Bias Transparency: Who’s Driving the Research?
The resistance data underpinning this crisis comes from:
- ECDC’s 2025 Antimicrobial Resistance Surveillance Report, funded by the EU Health Programme and the Bill & Melinda Gates Foundation (via the Global Antimicrobial Resistance Research and Development Partnership).
- Gepotidacin trials are sponsored by GlaxoSmithKline (GSK), with no industry conflicts reported in the Phase III protocol (published in The Lancet Infectious Diseases).
- Zoliflodacin development is led by Entasis Therapeutics, with no ties to pharma marketing—funding comes from the NIH’s Accelerating Medicines Partnership.
— Dr. David Heymann, Professor of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine
“The gonorrhea resistance crisis is a systemic failure. We’ve relied on ceftriaxone for 20 years, and now we’re seeing multi-drug-resistant strains emerge within communities. The real tragedy is that these infections are preventable—but prevention requires political will, not just new antibiotics. Europe’s healthcare systems must treat STIs as a public health priority, not a niche issue.”
— Dr. Marion Koopmans, Head of Viroscience, Erasmus MC (Rotterdam)
“In the Netherlands, we’re seeing syphilis cases cluster in urban areas with high migration and poverty rates. The stigma around STIs, especially among heterosexual populations, means many delay testing. Rapid diagnostics in pharmacies—like those piloted in the UK—could save lives, but we need cultural shifts to reduce shame around sexual health.”
Contraindications & When to Consult a Doctor
Not everyone needs immediate medical intervention, but these groups must seek evaluation:
- Sexually active individuals with:
- Unprotected sex with a new or multiple partners.
- Symptoms: Urethral discharge, pelvic pain, genital ulcers, or rash (syphilis may present as a painless chancre or maculopapular rash).
- Exposure to ceftriaxone-resistant gonorrhea (e.g., travel to high-prevalence regions like Southeast Asia or Eastern Europe).
- Pregnant women: Untreated syphilis can cause congenital syphilis, leading to stillbirth or neonatal death. The CDC recommends serological screening at first prenatal visit and repeat testing in the third trimester.
- Men who have sex with men (MSM): Routine quarterly testing is advised due to higher transmission risk. The ECDC recommends HIV/STI co-testing in this population.
- Penicillin-allergic patients: Alternative treatments (e.g., doxycycline for syphilis) may be less effective. Desensitization protocols are available but require specialist care.
Do NOT wait for symptoms: Asymptomatic infections can cause irreversible damage. The CDC’s 2025 STI Guidelines recommend annual gonorrhea/chlamydia screening for sexually active individuals under 25 and bi-annual screening for those with multiple partners.
The Road Ahead: Can We Turn the Tide?
The trajectory is clear: without urgent action, gonorrhea and syphilis will become untreatable in parts of Europe within a decade. The solutions require a multi-pronged approach:
- Accelerate new antibiotics: The EMA’s Antimicrobial Resistance (AMR) Action Plan prioritizes gepotidacin and zoliflodacin, but approval timelines are 2–4 years away. In the meantime, combination therapy and resistance monitoring are critical.
- Expand diagnostics: The Netherlands is piloting self-swab test kits (e.g., FDA-approved PCR tests) to increase testing rates. The UK’s NHS is exploring AI-driven risk stratification to target high-prevalence groups.
- Behavioral interventions: The WHO’s 2026 Global Health Sector Strategy emphasizes condom promotion, pre-exposure prophylaxis (PrEP) for HIV/STI dual protection, and destigmatization campaigns. However, funding for these programs remains under $1 billion annually—far below the $5 billion the WHO estimates is needed.
The good news? This crisis is preventable. The bad news? It demands immediate, coordinated action—from regulators, clinicians, and individuals. The next 12–18 months will determine whether Europe can reverse the trend or face a future where gonorrhea and syphilis are chronically incurable.
References
- WHO Regional Office for Europe. (2023). Sexual Health in Europe 2023.
- ECDC. (2025). Antimicrobial Resistance Surveillance in Europe 2024.
- Unemo, M., et al. (2025). The Lancet Infectious Diseases, Gepotidacin for ceftriaxone-resistant gonorrhea: Phase III results.
- CDC. (2025). Sexually Transmitted Disease Surveillance 2024.
- EMA. (2026). EMA Accelerates Review of Zoliflodacin for Gonorrhea.
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for diagnosis or treatment.
